Regulation of eIF4E activity for migraine therapy
View Patent ↗The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.
1. A method of preventing, treating, or inhibiting migraine in a human subject, comprising administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine by:
suppressing or inhibiting translation of at least one eIF4E-dependent mRNA in the subject;
suppressing or inhibiting eIF4E activity in the subject;
suppressing or inhibiting phosphorylation of 4E-BP or Ser209 of eIF4E in the subject; and/or
suppressing or inhibiting MNK activity in the subject.
2. The method of claim 1 , further comprising additionally administering to the subject a second therapeutic selected from cercosporamide, eFT508, 4EGI-1, a CGRP inhibitor, a gepant, a triptan, an ergotamine, an antiemetic, a NSAID or a non-narcotic analgesic, an opiate analgesic, a non-opiate analgesic, a steroid, lidocaine; valproic acid; or propofol.
3. The method of claim 2 , wherein the first therapeutic and second therapeutic are co-formulated.
4. The method of claim 2 , wherein the first therapeutic and the second therapeutic are not co-formulated.
5. The method of claim 4 , wherein the first therapeutic and the second therapeutic are delivered at distinct times.
6. The method of claim 1 , wherein the first therapeutic is delivered daily.
7. The method of claim 1 , wherein the first therapeutic is delivered upon onset of at least one migraine symptom.
8. The method of claim 3 , wherein the first and second therapeutics are delivered daily.
9. The method of claim 3 , wherein the first and second therapeutics are delivered upon onset of at least one migraine symptom.
10. The method of claim 4 , wherein one of the first therapeutic or second therapeutic is delivered daily, while the other of the first therapeutic or second therapeutic is delivered upon onset of at least one migraine symptom.
11. The method of claim 4 , wherein the first therapeutic and second therapeutic are both delivered daily.
12. The method of claim 4 , wherein the first therapeutic and second therapeutic are both delivered upon onset of at least one migraine symptom.
13. The method of claim 1 , wherein the subject in a human.
14. The method of claim 1 , wherein the subject has previously experienced migraine.
15. A composition comprising:
at least two of cercosporamide, eFT508, or 4EGI-1, both in an effective amount to prevent, treat, or inhibit migraine in a subject by:
suppressing or inhibiting translation of at least one eIF4E-dependent mRNA in the subject;
suppressing or inhibiting eIF4E activity in the subject;
suppressing or inhibiting phosphorylation of 4E-BP or Ser209 of eIF4E in the subject; and/or
suppressing or inhibiting MNK activity in the subject; and
a pharmaceutically acceptable carrier.
16. A composition comprising:
at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an effective amount to prevent, treat, or inhibit migraine in a subject by:
suppressing or inhibiting translation of at least one eIF4E-dependent mRNA in the subject;
suppressing or inhibiting eIF4E activity in the subject;
suppressing or inhibiting phosphorylation of 4E-BP or Ser209 of eIF4E in the subject; and/or
suppressing or inhibiting MNK activity in the subject; and
a pharmaceutically acceptable carrier.
17. The method of claim 1 , wherein the first therapeutic is cercosporamide.
18. The method of claim 1 , wherein the first therapeutic is, eFT508.
19. The method of claim 1 , wherein the first therapeutic is 4EGI-1.